For: | Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 2010; 16(19): 2421-2427 [PMID: 20480530 DOI: 10.3748/wjg.v16.i19.2421] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v16/i19/2421.htm |
Number | Citing Articles |
1 |
Francesco Crea, Stefania Nobili, Elisa Paolicchi, Gabriele Perrone, Cristina Napoli, Ida Landini, Romano Danesi, Enrico Mini. Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resistance Updates 2011; 14(6): 280 doi: 10.1016/j.drup.2011.08.001
|
2 |
Carmen Salguero-Aranda, Daniel Sancho-Mensat. Clinical Implications of STAT6 mRNA and Protein Knockdown in Human Colon Adenocarcinoma Cell Line, HT-29. Colorectal Cancer 2019; 8(1) doi: 10.2217/crc-2019-0004
|
3 |
Theodore Vougiouklakis, Benjamin J. Bernard, Nupur Nigam, Kyunghee Burkitt, Yusuke Nakamura, Vassiliki Saloura. Clinicopathologic significance of protein lysine methyltransferases in cancer. Clinical Epigenetics 2020; 12(1) doi: 10.1186/s13148-020-00897-3
|
4 |
Kai-Yuan Lin, Chein Tai, Jung-Chin Hsu, Chien-Feng Li, Chia-Lang Fang, Hsi-Chin Lai, You-Cheng Hseu, Yi-Feng Lin, Yih-Huei Uen, Terence Lee. Overexpression of Nuclear Protein Kinase CK2 α Catalytic Subunit (CK2α) as a Poor Prognosticator in Human Colorectal Cancer. PLoS ONE 2011; 6(2): e17193 doi: 10.1371/journal.pone.0017193
|
5 |
H. Tamagawa, T. Oshima, M. Numata, N. Yamamoto, M. Shiozawa, S. Morinaga, Y. Nakamura, M. Yoshihara, Y. Sakuma, Y. Kameda, M. Akaike, N. Yukawa, Y. Rino, M. Masuda, Y. Miyagi. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. European Journal of Surgical Oncology (EJSO) 2013; 39(6): 655 doi: 10.1016/j.ejso.2013.02.023
|
6 |
Tian Qing, Zhang Yamin, Wang Guijie, Jin Yan, Shen Zhongyang. STAT6 silencing induces hepatocellular carcinoma-derived cell apoptosis and growth inhibition by decreasing the RANKL expression. Biomedicine & Pharmacotherapy 2017; 92: 1 doi: 10.1016/j.biopha.2017.05.029
|
7 |
Laura Vilorio-Marqués, Vicente Martín, Cristina Diez-Tascón, María Francisca González-Sevilla, Tania Fernández-Villa, Emiliano Honrado, Veronica Davila-Batista, Antonio J. Molina. The role of EZH2 in overall survival of colorectal cancer: a meta-analysis. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-13670-z
|
8 |
Shuling Chen, Lixia Huang, Kaiyu Sun, Dexi Wu, Minrui Li, Manying Li, Bihui Zhong, Minhu Chen, Shenghong Zhang, Rossella Rota. Enhancer of Zeste Homolog 2 as an Independent Prognostic Marker for Cancer: A Meta-Analysis. PLOS ONE 2015; 10(5): e0125480 doi: 10.1371/journal.pone.0125480
|
9 |
Guanglin Cui, Ziqi Wang, Hanzhe Liu, Zhigang Pang. Cytokine-mediated crosstalk between cancer stem cells and their inflammatory niche from the colorectal precancerous adenoma stage to the cancerous stage: Mechanisms and clinical implications. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1057181
|
10 |
Tao Huang, Chengyuan Lin, Linda L. D. Zhong, Ling Zhao, Ge Zhang, Aiping Lu, Jiang Wu, Zhaoxiang Bian. Targeting histone methylation for colorectal cancer. Therapeutic Advances in Gastroenterology 2017; 10(1): 114 doi: 10.1177/1756283X16671287
|
11 |
Claudio Rizzi, Palmina Cataldi, Aldo Iop, Miriam Isola, Riccardo Sgarra, Guidalberto Manfioletti, Vincenzo Giancotti. The expression of the high-mobility group A2 protein in colorectal cancer and surrounding fibroblasts is linked to tumor invasiveness. Human Pathology 2013; 44(1): 122 doi: 10.1016/j.humpath.2012.05.001
|
12 |
Yannick Verhoeven, Sam Tilborghs, Julie Jacobs, Jorrit De Waele, Delphine Quatannens, Christophe Deben, Hans Prenen, Patrick Pauwels, Xuan Bich Trinh, An Wouters, Evelien L.J. Smits, Filip Lardon, Peter A. van Dam. The potential and controversy of targeting STAT family members in cancer. Seminars in Cancer Biology 2020; 60: 41 doi: 10.1016/j.semcancer.2019.10.002
|
13 |
Samar M. Abdel Raouf, Taiseer R. Ibrahim, Lobna A. Abdelaziz, Mohamed I. Farid, Salem Y Mohamed. Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer. Journal of Gastrointestinal Cancer 2021; 52(1): 90 doi: 10.1007/s12029-019-00344-4
|
14 |
Fábio Pereira, Antonio Barbáchano, Prashant K. Singh, Moray J. Campbell, Alberto Muñoz, María Jesús Larriba. Vitamin D has wide regulatory effects on histone demethylase genes. Cell Cycle 2012; 11(6): 1081 doi: 10.4161/cc.11.6.19508
|
15 |
Tao Jiang, Yan Wang, Fei Zhou, Guanghui Gao, Shengxiang Ren, Caicun Zhou. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis. Oncotarget 2016; 7(4): 4584 doi: 10.18632/oncotarget.6612
|
16 |
Mozhdeh Zamani, Seyed Vahid Hosseini, Pooneh Mokarram. Epigenetic biomarkers in colorectal cancer: premises and prospects. Biomarkers 2018; 23(2): 105 doi: 10.1080/1354750X.2016.1252961
|
17 |
Cuiping Fu, Liyan Jiang, Shengyu Hao, Zilong Liu, Suling Ding, Weiwei Zhang, Xiangdong Yang, Shanqun Li. Activation of the IL-4/STAT6 Signaling Pathway Promotes Lung Cancer Progression by Increasing M2 Myeloid Cells. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.02638
|
18 |
Lucy Jankova, Owen F. Dent, Mark P. Molloy, Charles Chan, Pierre H. Chapuis, Viive M. Howell, Stephen J. Clarke. Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. PROTEOMICS – Clinical Applications 2015; 9(11-12): 1078 doi: 10.1002/prca.201400177
|
19 |
Xinhua Wang, Hongqing Zhao, Lei Lv, Liang Bao, Xun Wang, Shuguang Han. Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis. Scientific Reports 2016; 6(1) doi: 10.1038/srep19239
|
20 |
Jingchun Qin, Bin Wen, Yuqi Liang, Weitao Yu, Huixuan Li. Histone Modifications and their Role in Colorectal Cancer (Review). Pathology & Oncology Research 2020; 26(4): 2023 doi: 10.1007/s12253-019-00663-8
|
21 |
Francesco Crea, Lorenzo Fornaro, Gianluca Masi, Alfredo Falcone, Romano Danesi, William Farrar. Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. Journal of Clinical Oncology 2011; 29(25): 3487 doi: 10.1200/JCO.2011.37.0122
|
22 |
M Koppens, M van Lohuizen. Context-dependent actions of Polycomb repressors in cancer. Oncogene 2016; 35(11): 1341 doi: 10.1038/onc.2015.195
|
23 |
Ana Catalina Rivera Rugeles, Yael Delgado-Ramirez, Luis I. Terrazas, Sonia Leon-Cabrera. Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. 2021; : 149 doi: 10.1016/B978-0-12-822028-3.00017-0
|
24 |
Stanleyson V. Hato, I. Jolanda M. de Vries, W. Joost Lesterhuis. STATing the importance of immune modulation by platinum chemotherapeutics. OncoImmunology 2012; 1(2): 234 doi: 10.4161/onci.1.2.18126
|
25 |
Xin Tang, Wenwei Cai, Jing Cheng, Ping Lu, Shaojun Ma, Chaoting Chen, Yi Chen, Yun Sun, Caofeng Wang, Ping Hu, Xiaomin Lv, G. Sun, Yu Wang, Jing Sheng. The histone H3 lysine-27 demethylase UTX plays a critical role in colorectal cancer cell proliferation. Cancer Cell International 2019; 19(1) doi: 10.1186/s12935-019-0841-y
|
26 |
Yan-Long Liu, Xu Gao, Yang Jiang, Gan Zhang, Zi-Cheng Sun, Bin-Bin Cui, Yan-Mei Yang. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer. Journal of Cancer Research and Clinical Oncology 2015; 141(4): 661 doi: 10.1007/s00432-014-1854-5
|
27 |
Li Jiang, Xu-Hai Zhao, Yin-Ling Mao, Jun-Feng Wang, Hui-Jun Zheng, Qing-Shan You. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6. Journal of Experimental & Clinical Cancer Research 2019; 38(1) doi: 10.1186/s13046-019-1428-0
|
28 |
Peng Gao, Guanghui Ren, Jiangjiu Liang, Ju Liu. STAT6 Upregulates NRP1 Expression in Endothelial Cells and Promotes Angiogenesis. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.823377
|
29 |
Yong Jin Cho, Soo Hee Kim, Eun Kyung Kim, Jung Woo Han, Kyoo-Ho Shin, Hyuk Hu, Kyung Sik Kim, Young Deuk Choi, Sunghoon Kim, Young Han Lee, Jin-Suck Suh, Joong Bae Ahn, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha, Sung-Taek Jung, Hyo Song Kim. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4066-6
|
30 |
Taj Mohammad, Prithvi Singh, Deeba Shamim Jairajpuri, Lamya Ahmed Al-Keridis, Nawaf Alshammari, Mohd. Adnan, Ravins Dohare, Md Imtaiyaz Hassan. Differential Gene Expression and Weighted Correlation Network Dynamics in High-Throughput Datasets of Prostate Cancer. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.881246
|
31 |
|
32 |
Martijn AJ Koppens, Gergana Bounova, Paulien Cornelissen-Steijger, Nienke de Vries, Owen J Sansom, Lodewyk FA Wessels, Maarten van Lohuizen. Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition. Oncotarget 2016; 7(43): 69816 doi: 10.18632/oncotarget.12002
|
33 |
Bin Xu, Samuel Abourbih, Kanishka Sircar, Wassim Kassouf, Jose Joao Mansure, Armen Aprikian, Simon Tanguay, Fadi Brimo. Enhancer of Zeste Homolog 2 Expression Is Associated With Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma: A Comparative Study and Review of the Literature. Archives of Pathology & Laboratory Medicine 2013; 137(10): 1326 doi: 10.5858/arpa.2012-0525-OA
|
34 |
Euan J. Rodger, Gregory Gimenez, Priyadarshana Ajithkumar, Peter A. Stockwell, Suzan Almomani, Sarah A. Bowden, Anna L. Leichter, Antonio Ahn, Sharon Pattison, John L. McCall, Sebastian Schmeier, Frank A. Frizelle, Michael R. Eccles, Rachel V. Purcell, Aniruddha Chatterjee. An epigenetic signature of advanced colorectal cancer metastasis. iScience 2023; 26(6): 106986 doi: 10.1016/j.isci.2023.106986
|
35 |
Antonios N. Gargalionis, Christina Piperi, Christos Adamopoulos, Athanasios G. Papavassiliou. Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. The International Journal of Biochemistry & Cell Biology 2012; 44(8): 1276 doi: 10.1016/j.biocel.2012.05.002
|
36 |
Saisai Li, Bo Sheng, Menghuang Zhao, Qi Shen, Haiyan Zhu, Xueqiong Zhu. The prognostic values of signal transducers activators of transcription family in ovarian cancer. Bioscience Reports 2017; 37(4) doi: 10.1042/BSR20170650
|
37 |
Min-Shan Chen, Yuan-Hung Lo, Xi Chen, Christopher S. Williams, Jessica M. Donnelly, Zachary K. Criss , Shreena Patel, Joann M. Butkus, Julien Dubrulle, Milton J. Finegold, Noah F. Shroyer.
Growth Factor–Independent 1 Is a Tumor Suppressor Gene in Colorectal Cancer. Molecular Cancer Research 2019; 17(3): 697 doi: 10.1158/1541-7786.MCR-18-0666
|
38 |
Hisao Kano, Tadatoshi Takayama, Yutaka Midorikawa, Hiroki Nagase. Promoter hypomethylation of RAR-related orphan receptor α 1 is correlated with unfavorable clinicopathological features in patients with colorectal cancer. BioScience Trends 2016; 10(3): 202 doi: 10.5582/bst.2016.01097
|
39 |
Lamia Abd Al Kader, Takashi Oka, Katsuyoshi Takata, Xu Sun, Hiaki Sato, Ichiro Murakami, Tomohiro Toji, Akihiro Manabe, Hiroshi Kimura, Tadashi Yoshino. In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Virchows Archiv 2013; 463(5): 697 doi: 10.1007/s00428-013-1428-y
|
40 |
Nikhil Baban Ghate, Sangnam Kim, Erin Spiller, Sungmin Kim, Yonghwan Shin, Suhn K. Rhie, Goar Smbatyan, Heinz‐Josef Lenz, Shannon M. Mumenthaler, Woojin An. VprBP directs epigenetic gene silencing through histone H2A phosphorylation in colon cancer. Molecular Oncology 2021; 15(10): 2801 doi: 10.1002/1878-0261.13068
|
41 |
Hye Lim Lee, Mi Hee Park, Ju Kyoung Song, Yu Yeon Jung, Youngsoo Kim, Kyung Bo Kim, Dae Yeon Hwang, Do Young Yoon, Min Jong Song, Sang Bae Han, Jin Tae Hong. Tumor growth suppressive effect of IL-4 through p21-mediated activation of STAT6 in IL-4Rα overexpressed melanoma models. Oncotarget 2016; 7(17): 23425 doi: 10.18632/oncotarget.8111
|
42 |
Hisae Iinuma, Toshiaki Watanabe, Koshi Mimori, Junko Tamura, Miki Adachi, Naoko Hayashi, Keijiro Nozawa, Soichiro Ishihara, Keiji Matsuda, Hideo Baba, Ryoji Fukushima, Kota Okinaga, Mitsuru Sasako, Masaki Mori. Reply to F. Crea et al. Journal of Clinical Oncology 2011; 29(25): 3488 doi: 10.1200/JCO.2011.37.2276
|
43 |
Qi Zhang, Qi Han, Jie Zi, Jinlong Ma, Huihui Song, Yulu Tian, Mary McGrath, Chunhua Song, Zheng Ge. Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms. Genes & Diseases 2019; 6(3): 276 doi: 10.1016/j.gendis.2019.05.001
|
44 |
D. A. Chetverina, D. V. Lomaev, P. G. Georgiev, M. M. Erokhin. Genetic Impairments of PRC2 Activity in Oncology: Problems and Prospects. Russian Journal of Genetics 2021; 57(3): 258 doi: 10.1134/S1022795421030042
|
45 |
Jiaqiu Li, Hongchuan Jin, Xian Wang. Epigenetic Biomarkers: Potential Applications in Gastrointestinal Cancers. ISRN Gastroenterology 2014; 2014: 1 doi: 10.1155/2014/464015
|
46 |
Yael Delgado‑Ramirez, Vaneesa Colly, Giovanni Villanueva Gonzalez, Sonia Leon‑Cabrera. Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review). Oncology Letters 2020; 20(1): 455 doi: 10.3892/ol.2020.11614
|
47 |
Lamia Abdalkader, Takashi Oka, Katsuyoshi Takata, Hiaki Sato, Ichiro Murakami, Arie P. Otte, Tadashi Yoshino. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms. Pathology 2016; 48(5): 467 doi: 10.1016/j.pathol.2016.05.002
|
48 |
Wei Liu, Feiyue Zhu, Jiazhuo Yan, Yi Liu, Cong Chen, Kaixuan Zhang, Xielan Zhao, Jingyuan Chen. <p>Identification and Validation of <em>STAT6</em> as a Prognostic and Predictive Biomarker in Acute Myeloid Leukemia</p>. OncoTargets and Therapy 2020; : 11165 doi: 10.2147/OTT.S272757
|
49 |
Yawei Wang, Fang Gao, Meng Zhao, Bing Li, Dan Xing, Jie Wang, Yang Yang. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta‐analysis. Journal of Cellular and Molecular Medicine 2016; 20(5): 836 doi: 10.1111/jcmm.12791
|
50 |
Lukas F. Mager, Marie-Hélène Wasmer, Tilman T. Rau, Philippe Krebs. Cytokine-Induced Modulation of Colorectal Cancer. Frontiers in Oncology 2016; 6 doi: 10.3389/fonc.2016.00096
|
51 |
Chun-Mao Lin, Chia-Lang Fang, You-Cheng Hseu, Chun-Liang Chen, Jin-Wun Wang, Sheng-Lung Hsu, Ming-Dao Tu, Shih-Ting Hung, Chein Tai, Yih-Huei Uen, Kai-Yuan Lin, Irina V. Lebedeva. Clinical and Prognostic Implications of Transcription Factor SOX4 in Patients with Colon Cancer. PLoS ONE 2013; 8(6): e67128 doi: 10.1371/journal.pone.0067128
|
52 |
Mushriq Al-Jazrawe, Steven Xu, Raymond Poon, Qingxia Wei, Joanna Przybyl, Sushama Varma, Matt van de Rijn, Benjamin A. Alman. CD142 Identifies Neoplastic Desmoid Tumor Cells, Uncovering Interactions Between Neoplastic and Stromal Cells That Drive Proliferation. Cancer Research Communications 2023; 3(4): 697 doi: 10.1158/2767-9764.CRC-22-0403
|
53 |
Antja-Voy Hartley, Matthew Martin, Tao Lu. Advances in the Molecular Understanding of Colorectal Cancer. 2019; doi: 10.5772/intechopen.82572
|
54 |
Sarah Derks, Manon van Engeland. Epigenetic Therapy of Cancer. 2014; : 283 doi: 10.1007/978-3-642-38404-2_12
|
55 |
Nikhil Chandnani, Vedika Shrirang Choudhari, Rajat Talukdar, Sudeshna Rakshit, Geetha Shanmugam, Shiuli Guchait, Ishika Gupta, Melvin George, Koustav Sarkar. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC). Medical Oncology 2023; 40(7) doi: 10.1007/s12032-023-02053-2
|
56 |
Mónica G. Mendoza-Rodríguez, C. Ángel Sánchez-Barrera, Blanca E. Callejas, Verónica García-Castillo, Diana L. Beristain-Terrazas, Norma L. Delgado-Buenrostro, Yolanda I. Chirino, Sonia A. León-Cabrera, Miriam Rodríguez-Sosa, Emma Bertha Gutierrez-Cirlos, Carlos Pérez-Plasencia, Felipe Vaca-Paniagua, Marco Antonio Meraz-Ríos, Luis I. Terrazas. Use of STAT6 Phosphorylation Inhibitor and Trimethylglycine as New Adjuvant Therapies for 5-Fluorouracil in Colitis-Associated Tumorigenesis. International Journal of Molecular Sciences 2020; 21(6): 2130 doi: 10.3390/ijms21062130
|
57 |
Nikhil B. Ghate, Sungmin Kim, Yonghwan Shin, Jinman Kim, Michael Doche, Scott Valena, Alan Situ, Sangnam Kim, Suhn K. Rhie, Heinz-Josef Lenz, Tobias S. Ulmer, Shannon M. Mumenthaler, Woojin An. Phosphorylation and stabilization of EZH2 by DCAF1/VprBP trigger aberrant gene silencing in colon cancer. Nature Communications 2023; 14(1) doi: 10.1038/s41467-023-37883-1
|
58 |
F. Crea, L. Fornaro, E. Paolicchi, G. Masi, P. Frumento, F. Loupakis, L. Salvatore, C. Cremolini, M. Schirripa, F. Graziano, M. Ronzoni, V. Ricci, W.L. Farrar, A. Falcone, R. Danesi. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology 2012; 23(5): 1207 doi: 10.1093/annonc/mdr387
|
59 |
Alireza Lorzadeh, Maile Romero-Wolf, Ajay Goel, Unmesh Jadhav. Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation. Gastroenterology 2021; 160(7): 2267 doi: 10.1053/j.gastro.2021.03.036
|
60 |
Ajay Goel, C. Richard Boland. Epigenetics of Colorectal Cancer. Gastroenterology 2012; 143(6): 1442 doi: 10.1053/j.gastro.2012.09.032
|
61 |
Hiromu Suzuki, Eiichiro Yamamoto, Hiroshi Nakase, Tamotsu Sugai. DNA and Histone Methylation as Cancer Targets. Cancer Drug Discovery and Development 2017; : 461 doi: 10.1007/978-3-319-59786-7_17
|
62 |
Zoe Veneti, Kalliopi Gkouskou, Aristides Eliopoulos. Polycomb Repressor Complex 2 in Genomic Instability and Cancer. International Journal of Molecular Sciences 2017; 18(8): 1657 doi: 10.3390/ijms18081657
|
63 |
Mousumi Mahapatro, Lena Erkert, Christoph Becker. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells 2021; 10(1): 111 doi: 10.3390/cells10010111
|
64 |
Yanxin An, Yi Zhou, Gui Ren, Qifei Tian, Yuanyuan Lu, Hongtao Li, Kai Li, Tao Su, Bin Xu, Shuo Chen, Tao Wang, Xipeng Zhang, Yongzhan Nie, Xin Wang, Qingchuan Zhao. Elevated expression of MGb2-Ag/TRAK1 is correlated with poor prognosis in patients with colorectal cancer. International Journal of Colorectal Disease 2011; 26(11): 1397 doi: 10.1007/s00384-011-1237-1
|
65 |
Lauren Krill, Wei Deng, Ramez Eskander, David Mutch, Susan Zweizig, Bang Hoang, Olga Ioffe, Leslie Randall, Heather Lankes, David S. Miller, Michael Birrer. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology 2020; 156(2): 423 doi: 10.1016/j.ygyno.2019.12.003
|
66 |
Yael Delgado-Ramirez, Angel Ocaña-Soriano, Yadira Ledesma-Soto, Jonadab E. Olguín, Joselín Hernandez-Ruiz, Luis I. Terrazas, Sonia Leon-Cabrera. STAT6 Is Critical for the Induction of Regulatory T Cells In Vivo Controlling the Initial Steps of Colitis-Associated Cancer. International Journal of Molecular Sciences 2021; 22(8): 4049 doi: 10.3390/ijms22084049
|
67 |
Antonio Andrade-Meza, Luis E. Arias-Romero, Leonel Armas-López, Federico Ávila-Moreno, Yolanda I. Chirino, Norma L. Delgado-Buenrostro, Verónica García-Castillo, Emma B. Gutiérrez-Cirlos, Imelda Juárez-Avelar, Sonia Leon-Cabrera, Mónica G. Mendoza-Rodríguez, Jonadab E. Olguín, Araceli Perez-Lopez, Carlos Pérez-Plasencia, José L. Reyes, Yesennia Sánchez-Pérez, Luis I. Terrazas, Felipe Vaca-Paniagua, Olga Villamar-Cruz, Miriam Rodríguez-Sosa. Mexican Colorectal Cancer Research Consortium (MEX-CCRC): Etiology, Diagnosis/Prognosis, and Innovative Therapies. International Journal of Molecular Sciences 2023; 24(3): 2115 doi: 10.3390/ijms24032115
|
68 |
Francesco Crea, Lorenzo Fornaro, Guido Bocci, Lei Sun, William L. Farrar, Alfredo Falcone, Romano Danesi. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer and Metastasis Reviews 2012; 31(3-4): 753 doi: 10.1007/s10555-012-9387-3
|
69 |
James B Rawson, Bharati Bapat. Epigenetic biomarkers in colorectal cancer diagnostics. Expert Review of Molecular Diagnostics 2012; 12(5): 499 doi: 10.1586/erm.12.39
|
70 |
Evelyne Lima-Fernandes, Alex Murison, Tiago da Silva Medina, Yadong Wang, Anqi Ma, Cherry Leung, Genna M. Luciani, Jennifer Haynes, Aaron Pollett, Constanze Zeller, Shili Duan, Antonija Kreso, Dalia Barsyte-Lovejoy, Bradly G. Wouters, Jian Jin, Daniel D. De Carvalho, Mathieu Lupien, Cheryl H. Arrowsmith, Catherine A. O’Brien. Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. Nature Communications 2019; 10(1) doi: 10.1038/s41467-019-09309-4
|
71 |
Carmen Behrens, Luisa M. Solis, Heather Lin, Ping Yuan, Ximing Tang, Humam Kadara, Erick Riquelme, Hector Galindo, Cesar A. Moran, Neda Kalhor, Stephen G. Swisher, George R. Simon, David J. Stewart, J. Jack Lee, Ignacio I. Wistuba. EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma. Clinical Cancer Research 2013; 19(23): 6556 doi: 10.1158/1078-0432.CCR-12-3946
|
72 |
Axelle E M Larue, Yaser Atlasi. The epigenetic landscape in intestinal stem cells and its deregulation in colorectal cancer. Stem Cells 2024; 42(6): 509 doi: 10.1093/stmcls/sxae027
|
73 |
Sónia Carvalho, Micaela Freitas, Luís Antunes, Sara Monteiro-Reis, Marcia Vieira-Coimbra, Ana Tavares, Sofia Paulino, José Flávio Videira, Carmen Jerónimo, Rui Henrique. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer. Journal of Cancer Research and Clinical Oncology 2018; 144(11): 2127 doi: 10.1007/s00432-018-2733-2
|
74 |
Szofia Hajósi-Kalcakosz, Eszter Vincze, Katalin Dezső, Sándor Paku, András Rókusz, Zoltán Sápi, Erika Tóth, Péter Nagy. EZH2 is a sensitive marker of malignancy in salivary gland tumors. Diagnostic Pathology 2015; 10(1) doi: 10.1186/s13000-015-0392-z
|
75 |
Kewen He, Hampartsoum B. Barsoumian, Nahum Puebla-Osorio, Yun Hu, Duygu Sezen, Mark D. Wasley, Genevieve Bertolet, Jie Zhang, Carola Leuschner, Liangpeng Yang, Claudia S. Kettlun Leyton, Natalie Wall Fowlkes, Morgan Maureen Green, Lisa Hettrick, Dawei Chen, Fatemeh Masrorpour, Meidi Gu, Hadi Maazi, Alexey S. Revenko, Maria Angelica Cortez, James W. Welsh. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer. Cancer Immunology Research 2023; 11(4): 486 doi: 10.1158/2326-6066.CIR-22-0547
|
76 |
Xinliang Zhan, Yan Wang, Jing Yang. Janus Kinase/Signal Converters, and the Transcriptional Activator Signaling Pathway Promotes Lung Cancer Through Increasing M2 Macrophage. Journal of Biomaterials and Tissue Engineering 2021; 11(4): 605 doi: 10.1166/jbt.2021.2566
|
77 |
Jonathan R. Hart, Lujian Liao, John R. Yates, Peter K. Vogt. Essential role of Stat3 in PI3K-induced oncogenic transformation. Proceedings of the National Academy of Sciences 2011; 108(32): 13247 doi: 10.1073/pnas.1110486108
|
78 |
Hiroyoshi Kurihara, Reo Maruyama, Kazuya Ishiguro, Shinichi Kanno, Itaru Yamamoto, Keisuke Ishigami, Kei Mitsuhashi, Hisayoshi Igarashi, Miki Ito, Tokuma Tanuma, Yasutaka Sukawa, Kenji Okita, Tadashi Hasegawa, Kohzoh Imai, Hiroyuki Yamamoto, Yasuhisa Shinomura, Katsuhiko Nosho. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. Oncotarget 2016; 7(11): 12704 doi: 10.18632/oncotarget.7260
|
79 |
Jialiang Shao, Tiezhu Shi, Lianheng Chen, Xiang Wang, Hua Yu, Ninghan Feng, Xiongjun Wang. AF9 targets acetyl-modified STAT6 to diminish purine metabolism and accelerate cell apoptosis during metastasis. Cell Death & Differentiation 2023; 30(7): 1695 doi: 10.1038/s41418-023-01172-7
|
80 |
Bin Liu, Bo Pang, Qirui Wang, Shengji Yang, Taihong Gao, Qian Ding, Huajie Liu, Yihang Yang, Haitao Fan, Rui Zhang, Tao Xin, Guangming Xu, Qi Pang. EZH2 upregulation correlates with tumor invasiveness, proliferation, and angiogenesis in human pituitary adenomas. Human Pathology 2017; 66: 101 doi: 10.1016/j.humpath.2017.03.028
|
81 |
Carmen Salguero-Aranda, Daniel Sancho-Mensat, Beatriz Canals-Lorente, Sabena Sultan, Ajan Reginald, Lee Chapman, Sumitra Deb. STAT6 knockdown using multiple siRNA sequences inhibits proliferation and induces apoptosis of human colorectal and breast cancer cell lines. PLOS ONE 2019; 14(5): e0207558 doi: 10.1371/journal.pone.0207558
|
82 |
Anne Benard, Inès J. Goossens-Beumer, Anneke Q. van Hoesel, Hamed Horati, Hein Putter, Eliane C. M. Zeestraten, Cornelis J. H. van de Velde, Peter J. K. Kuppen, Richard L. Eckert. Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone Modification H3K27me3 in Colorectal Cancer. PLoS ONE 2014; 9(9): e108265 doi: 10.1371/journal.pone.0108265
|
83 |
Daisy PF Tsang, Alfred SL Cheng. Epigenetic regulation of signaling pathways in cancer: Role of the histone methyltransferase EZH2. Journal of Gastroenterology and Hepatology 2011; 26(1): 19 doi: 10.1111/j.1440-1746.2010.06447.x
|
84 |
Bettina Fussbroich, Nina Wagener, Stephan Macher-Goeppinger, Axel Benner, Maria Fälth, Holger Sültmann, Angela Holzer, Karin Hoppe-Seyler, Felix Hoppe-Seyler, Moray Campbell. EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells. PLoS ONE 2011; 6(7): e21651 doi: 10.1371/journal.pone.0021651
|
85 |
Yu Wang, Liming Zhu, Mei Guo, Gang Sun, Kun Zhou, Wenjing Pang, Dachun Cao, Xin Tang, Xiangjun Meng. Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2. Cell Death Discovery 2021; 7(1) doi: 10.1038/s41420-021-00402-6
|
86 |
Szofia Hajósi-Kalcakosz, Katalin Dezső, Edina Bugyik, Csaba Bödör, Sándor Paku, Zoltán Pávai, Judit Halász, Krisztina Schlachter, Zsuzsa Schaff, Péter Nagy. Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors. Diagnostic Pathology 2012; 7(1) doi: 10.1186/1746-1596-7-86
|
87 |
Franziska Lea Schümann, Elisabeth Groß, Marcus Bauer, Christian Rohde, Sarah Sandmann, Denis Terziev, Lutz P. Müller, Guido Posern, Andreas Wienke, Falko Fend, Martin-Leo Hansmann, Wolfram Klapper, Andreas Rosenwald, Harald Stein, Martin Dugas, Carsten Müller-Tidow, Claudia Wickenhauser, Mascha Binder, Thomas Weber. Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas. Biomedicines 2021; 9(12): 1842 doi: 10.3390/biomedicines9121842
|
88 |
Elizabeth G. Demicco, Paul W. Harms, Rajiv M. Patel, Steven C. Smith, Davis Ingram, Keila Torres, Shannon L. Carskadon, Sandra Camelo-Piragua, Jonathan B. McHugh, Javed Siddiqui, Nallasivam Palanisamy, David R. Lucas, Alexander J. Lazar, Wei-Lien Wang. Extensive Survey of STAT6 Expression in a Large Series of Mesenchymal Tumors. American Journal of Clinical Pathology 2015; 143(5): 672 doi: 10.1309/AJCPN25NJTOUNPNF
|
89 |
Hao Huang, Yizhou Zheng, Linfu Li, Weimei Shi, Rui Zhang, Hai Liu, Zhixi Chen, Longhuo Wu. The Roles of post-translational Modifications and Coactivators of STAT6 Signaling in Tumor Growth and Progression. Future Medicinal Chemistry 2020; 12(21): 1945 doi: 10.4155/fmc-2020-0224
|
90 |
Sonia A. Leon-Cabrera, Emmanuel Molina-Guzman, Yael G. Delgado-Ramirez, Armando Vázquez-Sandoval, Yadira Ledesma-Soto, Carlos G. Pérez-Plasencia, Yolanda I. Chirino, Norma L. Delgado-Buenrostro, Miriam Rodríguez-Sosa, Felipe Vaca-Paniagua, Federico Ávila-Moreno, Emma B. Gutierrez-Cirlos, Luis E. Arias-Romero, Luis I. Terrazas. Lack of STAT6 Attenuates Inflammation and Drives Protection against Early Steps of Colitis-Associated Colon Cancer. Cancer Immunology Research 2017; 5(5): 385 doi: 10.1158/2326-6066.CIR-16-0168
|